Table 1

Demographics and baseline characteristics of patients with lupus membranous nephropathy

Filgotinib
200 mg (n=5)
Lanraplenib
30 mg (n=4)
Total
(n=9)
Age, median283628
Sex, n (%)
 Female4 (80.0)3 (75.0)7 (77.8)
 Male1 (20.0)1 (25.0)2 (22.2)
Race, n (%)
 Asian1 (20.0)0 (0.0)1 (11.1)
 Black3 (60.0)4 (100.0)7 (77.8)
 White1 (20.0)0 (0.0)1 (11.1)
Ethnicity, n (%)
 Hispanic or Latino0 (0.0)0 (0.0)0 (0.0)
 Not Hispanic or Latino5 (100.0)4 (100.0)9 (100.0)
Duration since LMN diagnosis in months, median7.910.97.9
Duration since kidney biopsy in months, median8.19.58.3
24-hour urine protein in g/day, median2.44.82.9
Spot UPCR in mg/mg, median1.94.22.1
24-hour UPCR in mg/mg, median1.64.22.4
eGFR in mL/min/1.73 m2, median100.4119.0101.0
SELENA-SLEDAI total score, median6.04.56.0
ANA positive, n (%)5 (100.0)4 (100.0)9 (100.0)
Anti-dsDNA positive, n (%)3 (60.0)4 (100.0)7 (77.8)
Prior csDMARD treatment, n (%)5 (100.0)4 (100.0)9 (100.0)
 Mycophenolate mofetil, n (%)3 (60.0)3 (75.0)6 (66.7)
 Cyclophosphamide, n (%)2 (40.0)2 (50.0)4 (44.4)
 Azathioprine, n (%)0 (0.0)1 (25.0)1 (11.1)
Concurrent glucocorticoid treatment, n (%)4 (80.0)3 (75.0)7 (77.8)
 Baseline dose in mg/day, mean (SD)13.1 (8.5)15.0 (5.0)13.9 (6.8)
  • Baseline spot UPCR was calculated as the mean of 2 morning void UPCR values.

  • ANA, antinuclear antibody (positive if ≥1:40 dilution); anti-dsDNA, anti-double-stranded DNA antibody; csDMARD, conventional synthetic disease modifying antirheumatic drug; eGFR, estimated glomerular filtration rate; SELENA-SLEDAI, Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; UPCR, urine protein to creatinine ratio.